This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
40


nanotimes


Companies Facts


types, different experimental setups, and different outcome measures. The first human clinical trials of the vaccine are expected to start in 2011. The origi- nal work on VXM01 was conducted at The Scripps Research Institute and the project was in-licensed by VAXIMM from Merck KGaA in 2008. http://www.vaximm.com


V


eeco Instruments Inc. (NASDAQ: VECO) announced that Thomas Gutierrez has been


appointed to its Board of Directors. Mr. Gutierrez, age 62, currently serves as President, Chief Executive Officer and Director of GT Solar International, Inc. (NASDAQ: SOLR), a global provider of polysilicon production technology, and sapphire and silicon crystalline growth systems and materials for the solar, LED and other specialty markets.


Furthermore, Veeco announced its financial results for the fourth quarter and full-year ended December


31, 2010. John R. Peeler, Veeco’s Chief Executive Officer, commented, “The fourth quarter of 2010 was the best in our history, and we are extremely proud of our performance. Revenues were $300 mil- lion, gross margin was 51% and net income was $97 million. Veeco’s revenues grew 8% sequentially and 152% from the fourth quarter of last year. Both Vee- co segments delivered excellent performance: LED & Solar revenues were up 6% sequentially to a record $258 million, and Data Storage revenues were up 21% to $42 million, our best quarter since 2008.


Full year 2010 results were also at record levels, with revenue of $933 million and net income of $261 million. These results were achieved through a com- bination of world-class products, a focus on high- growth market opportunities, operational excellence,


our flexible manufacturing strategy, and a deep commitment to satisfying our global customers.”


Veeco’s first quarter 2011 revenue is currently forecasted to be between $215 and $265 million. Earnings per share are currently forecasted to be between $0.94 to $1.31 on a GAAP basis and $1.02 to $1.39 on a non-GAAP basis. Please refer to the attached financial table for more details.


“With starting backlog of $555 million, and antici- pating strong first half 2011 bookings, we currently forecast that Veeco’s 2011 revenues will be greater than $1 billion, resulting in non-GAAP earnings per share of greater than $5.00,” continued Mr. Peeler. http://www.veeco.com


lithography systems with a vacuum compatible air- bearing based positioning system overcoming the li- mitations of roller bearings for future performance re- quirements. The new platform is designed to support both Vistec‘s Variable Shaped Beam (VSB) writers as well as the Multi Shaped Beam (MSB) lithography system currently under development.


V


The combination of the new highly sophisticated platform with advanced variable shaped beam elec- tron optics enables Vistec to address mask writing as well as electron-beam direct write application demands for future technology nodes according to the ITRS roadmap. In addition, a multitude of special application needs, e.g. in the micro- and nano-optics area will be met.


istec Electron Beam GmbH announced that the company is ready to provide its electron-beam


11-01 :: December 2010 / January 2011


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95
Produced with Yudu - www.yudu.com